Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...

India's pharma giant Sun Pharma is to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted ...

The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through ...

India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company ...

Sun Pharmaceutical has agreed to acquire Checkpoint Therapeutics for an aggregate consideration of up to $355m upfront.

Sun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company.

Sun Pharma has acquired Checkpoint Therapeutics for $355 million, enhancing its onco-dermatology portfolio with the ...

Mumbai-based Sun Pharmaceutical Industries has entered into an agreement with Checkpoint Therapeutics Inc, to acquire the ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Sun Pharmaceutical Industries has entered into a definitive agreement to acquire Checkpoint Therapeutics, Inc., a ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...